All the news Showing 4 of 64 articles from: Ns5A inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources 94% response rate to HCV treatment without ribavirin or interferon in harder-to-treat Keith Alcorn / 13 November 2012 Twelve weeks of treatment with a three-drug combination of new directly acting antivirals that contained neither pegylated interferon nor ribavirin led to a sustained virologic response 12 weeks after completion of treatment (SVR12) ... High rate of response to BMS HCV drugs in harder-to-treat patients – but interferon-free prospects differ by sub-genotype Keith Alcorn / 12 November 2012 Although an interferon-free combination of antiviral drugs developed by Bristol-Myers Squibb to treat hepatitis C was highly effective in curing the infection in previous null responders to treatment with HCV genotype 1b infection, ... Hepatitis C meds GS-7977, daclatasvir and asunaprevir look good in interferon-free combos Liz Highleyman / 20 April 2012 Most previously untreated people with chronic hepatitis C achieved an early cure with an all-oral combination of the HCV NS5A inhibitor daclatasvir plus the polymerase inhibitor GS-7977, researchers reported on ... New anti-hepatitis C drug BMS-790052 does well in Phase IIa study Michael Carter / 20 September 2011 Up to 83% of individuals with chronic hepatitis C virus achieved a sustained virological response after receiving the investigational drug BMS-790052 in combination with pegylated interferon and ribavirin, results of a study presented ... ← Prev1...34567Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive